Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression

Alcaro A, Cabib S, Ventura R, Puglisi-Allegra S (2002). Genotype- and experience-dependent susceptibility to depressive-like responses in the forced-swimming test. Psychopharmacology (Berlin) 164: 138–143.

American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. American Psychiatric Association: Washington, DC.

Barr AM, Markou A, Phillips AG (2002). A ‘crash’ course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23: 475–482.

Barr LC, Heninger GR, Goodman W, Charney DS, Price LH (1997). Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41: 949–954.

Belzung C, Le Pape G (1994). Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol Behav 56: 623–628.

Bilkei-Gorzo A, Racz I, Michel K, Zimmer A (2002). Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 22: 10046–10052.

Blier P (2003). The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13: 57–66.

Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ (1988). The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berlin) 95: 298–302.

Borsini F, Lecci A, Sessarego A, Frassine R, Meli A (1989). Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation. Psychopharmacology (Berlin) 97: 183–188.

Borsini F, Podhorna J, Marazziti D (2002). Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berlin) 163: 121–141.

Bourin M, Fiocco AJ, Clenet F (2001). How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16: 9–21.

Bouwknecht JA, Paylor R (2002). Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 136: 489–501.

Caccia S, Cappi M, Fracasso C, Garattini S (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berlin) 100: 509–514.

Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002). cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22: 3262–3268.

Cryan JF, Lucki I (2000). Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 295: 1120–1126.

Cryan JF, Markou A, Lucki I (2002a). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238–245.

Cryan JF, Page ME, Lucki I (2002b). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436: 197–205.

D’Sa C, Duman RS (2002). Antidepressants and neuroplasticity. Bipolar Disord 4: 183–194.

Detke MJ, Johnson J, Lucki I (1997). Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5: 107–112.

Detke MJ, Lucki I (1996). Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 73: 43–46.

Dulawa SC, Grandy DK, Low MJ, Paulus MP, Geyer MA (1999). Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19: 9550–9556.

Gelfin Y, Gorfine M, Lerer B (1998). Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 155: 290–292.

Geyer M, Markou A (1995). Animal models of psychiatric disorders. In: Bloom F, Kupfer D (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York. pp 787–798.

Geyer M, Markou A (2002). The role of preclinical models in the development of psychotropic drugs. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 446–455.

Griebel G, Belzung C, Perrault G, Sanger DJ (2000). Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology (Berlin) 148: 164–170.

Hiemke C, Hartter S (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85: 11–28.

Hirschfeld R, Weisssman M (2002). Risk factors for major depression and bipolar disorder. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1018–1025.

Karolewicz B, Paul IA (2001). Group housing of mice increases immobility and antidepressant sensitivity in the forced swim and tail suspension tests. Eur J Pharmacol 415: 197–201.

Kelliher P, Kelly JP, Leonard BE, Sanchez C (2003). Effects of acute and chronic administration of selective monoamine re-uptake inhibitors in the rat forced swim test. Psychoneuroendocrinology 28: 332–347.

Kim S, Lee S, Ryu S, Suk J, Park C (2002). Comparative analysis of the anxiety-related behaviors in four inbred mice. Behav Processes 60: 181–190.

Kokkinidis L, Zacharko RM, Predy PA (1980). Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharmacol Biochem Behav 13: 379–383.

Kopp C, Vogel E, Rettori MC, Delagrange P, Guardiola-Lemaitre B, Misslin R (1999). Effects of melatonin on neophobic responses in different strains of mice. Pharmacol Biochem Behav 63: 521–526.

Koran LM, Cain JW, Dominguez RA, Rush AJ, Thiemann S (1996). Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 153: 1450–1454.

Le Pen G, Gaudet L, Mortas P, Mory R, Moreau JL (2002). Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berlin) 161: 434–441.

Lucki I, Dalvi A, Mayorga AJ (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berlin) 155: 315–322.

Markou A, Hauger RL, Koob GF (1992). Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berlin) 109: 305–314.

Merali Z, Levac C, Anisman H (2003). Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biol Psychiatry 54: 552–565.

Merikangas K, Pine D (2002). Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 868–882.

Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE (1992). Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2: 43–49.

Ohl F, Roedel A, Binder E, Holsboer F (2003). Impact of high and low anxiety on cognitive performance in a modified hole board test in C57BL/6 and DBA/2 mice. Eur J Neurosci 17: 128–136.

Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327–336.

Prut L, Belzung C (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3–33.

Reneric JP, Bouvard M, Stinus L (2002). In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 136: 521–532.

Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805–809.

Shephard RA, Broadhurst PL (1982). Hyponeophagia and arousal in rats: effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, d-amphetamine and food deprivation. Psychopharmacology (Berlin) 78: 368–372.

Suckow RF, Zhang MF, Cooper TB (1992). Sensitive and selective liquid-chromatographic assay of fluoxetine and norfluoxetine in plasma with fluorescence detection after precolumn derivatization. Clin Chem 38: 1756–1761.

Tang X, Orchard SM, Sanford LD (2002). Home cage activity and behavioral performance in inbred and hybrid mice. Behav Brain Res 136: 555–569.

Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL et al (2003). Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA (‘Ecstasy’) in rats. Neuropsychopharmacology, doi: 10.1038/sj.npp.1300347.

Welker W (1957). ‘Free’ versus ‘forced’ exploration of a novel situation by rats. Psychol Rep 3: 95–108.

Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berlin) 134: 319–329.

Yilmazer-Hanke DM, Roskoden T, Zilles K, Schwegler H (2003). Anxiety-related behavior and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains. Behav Brain Res 145: 145–159.